Skip to content

A Clinical study to evaluate the efficacy of Vidanghaidagajadi lepa and Navaka kasaya in the management of Dadru Kustha - Dermatophytosis (Tinea corporis)

A CLINICAL STUDY TO EVALUATE THE EFFICACY OF VIDANGAIDAGAJADI LEPA AND NAVAKA KASHAYA IN THE MANAGEMENT OF DADRU KUSTHA - DERMATOPHYTOSIS (TINEA CORPORIS) - Clinical Study Report

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/05/067183
Enrollment
30
Registered
2024-05-10
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L089- Local infection of the skin and subcutaneous tissue, unspecified

Interventions

None listed

Sponsors

Dr K MALATHI
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Subjects who fulfill the diagnostic criteria, Subjects between the age group of 18 - 60 years irrespective of gender, Who are willing to sign the consent form of the present study.Subjects having chronicity below 2 years, Skin Patches measuring within 5×5cm, Skin patches over the Extremities, Abdomen, and back of the trunk only.

Exclusion criteria

Exclusion criteria: Patients with other Systemic diseases and Autoimmune diseases that may interfere with the course of treatment. Other Dermatophyte types. Skin patches measuring more than 5×5cm associated with Serious conditions like bleeding, oozing from the wound with a foul smell Skin patches located in Vital organs i.e., eyes, genitalia, etc. Pregnant women and Lactating mothers. Patients who are having uncontrolled Hypertension, Diabetes mellitus, Renal Pathological changes.

Design outcomes

Primary

MeasureTime frame
Questionnaires about intensity, frequency and nature of lesions will be made and the following will be taken as parameters. 1. KANDU – Itching 2. DAHA – Burning Sensation 3. TWAK RUKSHATHRRA– Roughness of the skin. Relief in signs and symptoms and significant improvement of subjective parameters tests to 50% baseline.Timepoint: Relief in signs and symptoms and significant improvement of objective and subjective parameters tests to 50% baseline within the period of 30days

Secondary

MeasureTime frame
Changes in ESR , Size and complexity of patchesTimepoint: Management period of 30 days Assessment for every 10days with active followup of one month

Countries

India

Contacts

Public ContactK Malathi

Dr. N.R.S Govt Ayurvedic Medical College Mahatmagandhi road governerpet vijayawada

bulliahshyam@gmail.com9885913505

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026